Corcept, Pharmakon Advisors L.P. deal

Corcept granted a Pharmakon Advisors fund rights to receive up to $45 million in royalties on Corcept's products in exchange for $30 million in cash. In April, Corcept launched Korlym mifepristone - its first marketed product - in the U.S. to treat Cushing's syndrome, a hormonal disorder caused by prolonged exposure to high levels of cortisol. Second quarter sales of Korlym were $875,000. ...